SAFC Enters South Korean BioPharma Market with CrystalGenomics Agreement
SAFC was pleased to announce a first ever agreement with South Korea-based CrystalGenomics that not only represents a foray into this market, but will also support next-generation NSAID product development.
St. Louis, MO – October 30, 2012 – Sigma-Aldrich Corporation (NASDAQ: SIAL) today announced that its custom manufacturing and services business unit, SAFC® (www.safcglobal.com), has signed an agreement with Seoul, South Korea-based CrystalGenomics to support the development of active pharmaceutical ingredients (APIs) for next-generation non-steroidal anti-inflammatory drugs (NSAID). The agreement represents SAFC's premier pre-formulation services contract into the growing South Korean pharmaceutical market.
CrystalGenomics is a clinical stage biopharmaceutical company that engages in the discovery and development of innovative drugs based on structural chemoproteomics, a technology designed to accelerate drug discovery. The company is developing three clinical stage candidates. The lead program is a next-generation NSAID for osteoarthritis and is in phase 3 development. In addition to next-generation NSAID, the company is developing multiple novel candidates in various stages of development for various therapeutic areas with focus on inflammation, oncology, CNS and infection.
Per the agreement, CrystalGenomics will employ SAFC's Pharmorphix® Pre-formulation Technology services which are based in Cambridge, UK, to enable understandings of the physical properties of APIs. The services can also aid in determining the selection of optimal crystallization processes, ensure batch-to-batch consistency in manufacturing and help to maintain efficacy and patient safety.
"Our expertise in the pre-formulation of pharmaceuticals has allowed us to engage with CrystalGenomics through this agreement and to introduce our unique technologies to the South Korea market," said SAFC President, Gilles Cottier. "As the drug discovery and development process becomes increasingly complex and expensive, we feel that our pre-formulation services are well-positioned to help pharmaceutical and biopharmaceutical companies around the globe to accelerate their pipelines."